



ASX Announcement

21 May 2025

Cambium Bio Limited Announces Board and Company Secretary Changes

Sydney, Australia; 21 May 2025: Cambium Bio Limited (ASX:CMB) (**Cambium Bio, Cambium** or **Company**), a clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications, today announces a series of Board and corporate governance changes effective 21 May 2025.

Key Highlights:

- **Retirement of long-serving Chairman:** Mr Barry Sechos will retire from the Board after 13 years of service as Director and Chairman.
- **Appointment of new Chairman:** Executive Director and Chief Scientific Officer Dr Edmund Waller will assume the role of Chairman, succeeding Mr Sechos.
- **Appointment of Independent Non-Executive Director:** A/Prof Denese Marks joins the Board, bringing 30 years' experience in blood and platelet-based therapeutics, including autologous serum tears for dry eye disease.
- **Strengthened corporate governance:** Acclime Australia appointed as outsourced Company Secretary, replacing Ms Helen Leung, who departs after four years' service.

Retirement of Mr Barry Sechos

Mr Barry Sechos will retire from the Cambium Bio Board, effective 21 May 2025. Mr Sechos has served as Director since 2012 and as non-executive Chairman since 2013, guiding Cambium Bio through its ASX listing, strategic acquisition of Cambium Medical Technologies, and recent advancement of the Company's lead biologic, Elate Ocular®, towards Phase 3 trials.

Karolis Rosickas, CEO of Cambium Bio, commented: "On behalf of the entire team, I extend my heartfelt thanks to Barry for his thirteen years of dedicated leadership. Barry's strategic insight, steady guidance and unwavering commitment laid the foundations for Cambium Bio's transformation into a late-stage ophthalmology innovator. We wish him every success in his well-deserved retirement."

Appointment of Dr Edmund Waller as Chairman

Concurrent with Mr Sechos' retirement, Executive Director and Chief Scientific Officer **Dr Edmund Waller, MD, PhD, FACP** will be appointed Chairman of the Board. Dr Waller is a co-founder of Cambium Medical Technologies, Professor of Haematology and Oncology at Emory University, and an internationally recognised expert in platelet and stem-cell therapeutics.

Appointment of A/Prof Denese Marks to the Board

The Board welcomes **Associate Professor Denese C Marks** as Independent Non-Executive Director, effective 21 May 2025. Dr Marks is National Research Program Leader – Product Development & Transfusion Studies at Australian Red Cross Lifeblood, with:

- 30 years' post-doctoral research including 20 years in research management and leadership;
- A H-index of 35, >130 peer-reviewed publications and >3,500 citations;
- Established expertise in platelet storage, pathogen reduction and clinical trials of novel blood products;
- Leadership roles including Board member and Conventional Components Team Co-Chair of the BEST Collaborative, and Chair of the ISBT Blood Components Working Party.

Dr Marks' deep knowledge of platelet-derived biologics and her pioneering work on autologous serum tears for dry eye disease aligns directly with Cambium Bio's mission to advance Elate Ocular® and other platelet-based therapies.

Corporate Secretarial Transition

To support the next phase of growth and professionalise its governance framework, Cambium Bio has appointed Mark Licciardo of **Acclime Corporate Services Australia Pty Ltd** (Acclime) as outsourced Company Secretary, effective 21 May 2025. Acclime is a

leading provider of corporate compliance and advisory services across the Asia Pacific region. Ms Helen Leung will step down as Company Secretary on the same date after four years of dedicated service. The Board thanks Helen for her valuable contributions to Cambium Bio's corporate governance and wishes her well in future endeavours.

- ENDS -

About Cambium Bio Limited

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Cambium Bio Limited.

For further information, please contact:

Acclime Australia – Company Secretary
Unit 2.06/31 Lexington Dr, Bella Vista NSW 2153, Australia

Cambium Bio Limited
16 Goodhope Street, Paddington, NSW 2021, Australia
ABN 13 127 035 358
Phone: 1300 995 098
www.cambium.bio